Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Pegylated mechano growth factor
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Modified peptide identity family
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Commercial identity or variant awaiting clarification.
Mechanism
IGF-related growth hypotheses; exact product identity is often unclear.
Evidence and critical reading
Reported scientific and empirical uses
Reported muscle and performance
Sold for post-workout recovery as a PEGylated MGF variant.
Human evidence
No clinical benefit established by reviewed FDA material.
Preclinical evidence
Endogenous splice-product biology does not validate a pegylated commercial peptide.
Critical reading and limitations
IGF-1 gene or non-PEG fragment evidence does not validate the PEGylated entity or claimed duration.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
100–400 mcg · Amount per administration
- Frequency
- After exercise per source; weekly count not fixed
- Duration
- 4–6 weeks
- Route
- Subcutaneous
- Context
- Handbook repair claim; PEG identity/human efficacy unverified.
- Presentation
- Not stated on selected page.
- Interpretation
- Regimen attributed to handbook, without clinical validation for this use; not a recommendation.
manual07 · Page 38 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
FDA identifies lack of human exposure data in its assessment and immunogenicity/identity concerns.
No validated human regimen was identified; PEGylation does not guarantee safety/equivalence.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
PEG-MGF · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
600 mcg/day for five days would imply 3 mg/week versus the written 2-mg limit; PEG-MGF handbooks also conflict. · manual01 · Page 98
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- R06
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026